 Home > Active Ingredient News > Study of Nervous System > Neurology: Don't just know about dementia, MCI before dementia is preventable and treatable, and it is more worthy of attention!

Neurology: Don't just know about dementia, MCI before dementia is preventable and treatable, and it is more worthy of attention!

 Last Update: 2021-10-09
 Source: Internet
 Author: User

Tags

mixed surface analysis

peach neurology

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Mild cognitive impairment (MCI) is an intermediate clinical state between normal cognition and dementia

Generally speaking, these standards include measurable cognitive deficits in at least one area, and there is no dementia or impaired daily function

In order to distinguish MCI into meaningful cognitive subtypes based on experience, experts in neurology apply actuarial methods to comprehensive neuropsychological data from the Alzheimer's Disease Research Center (ADRC) of the University of California, San Diego, to determine ADRC participation There is no cognitive subgroup of dementia among the patients, and the trajectories of cognition, biomarkers and neuropathology are studied

Researchers performed cluster analysis on baseline neuropsychological data (n = 738; average age 71.

The results identified five groups: the best cognition is normal (cognitive ability is higher than average CN; n = 130), typical CN (cognitive ability is generally n = 204); non-dementia MCI (naMCI; n = 104); dementia MCI (aMCI; n = 216); and mixed MCI (mMCI; n = 84)

The evolution process from CN to MCI to AD

In general, the progression of dementia in different MCI subtypes is different (mMCI> aMCI> naMCI), and the positive rate of CSF biomarkers in the mMCI group and the pathological rate of AD at autopsy are the highest

In summary, the study identified the subtypes of MCI and CN.

references:

Data-Driven vs Consensus Diagnosis of MCI Enhanced Sensitivity for Detection of Clinical, Biomarker, and Neuropathologic Outcomes.

Data-Driven vs Consensus Diagnosis of MCI Enhanced Sensitivity for Detection of Clinical, Biomarker, and Neuropathologic Outcomes.

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Pregabalin (CNS)

CAS No.: 148553-50-8

Pharmacy Grade

$1/KG FOB

Primidone CAS125-33-7

CAS No.: 125-33-7

Pharmaceutical Grade

$100/KG EXW

API Clomipramine HCl

CAS No.: 17321-77-6

Pharmacy Grade

$40-50/G FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.